Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
HS-20093 by GSK for Solid Tumor: Likelihood of Approval
HS-20093 is under clinical development by GSK and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Data Insights
Risk adjusted net present value: What is the current valuation of GSK's HS-20093?
HS-20093 is a monoclonal antibody conjugated commercialized by GSK, with a leading Phase I program in Solid Tumor. According to...